May 14 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it has approved Merck's MRK.N cancer drug to expand its use to two types adrenal gland tumors.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.